|
Aug 8
|
Nicox Extends Existing Flexible Equity Financing
|
|
Aug 7
|
Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical
|
|
Aug 5
|
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
|
|
Jul 17
|
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
|